APA (7th ed.) Citation

Douma, L. H., van der Noort, V., Lalezari, F., de Vries, J. F., Monkhorst, K., Smesseim, I., . . . de Gooijer, C. J. (2025). Pembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): Cohort 2 of a single-arm, phase 2 study. Lancet Oncology, 26(12), 1676. https://doi.org/10.1016/S1470-2045(25)00514-5

Chicago Style (17th ed.) Citation

Douma, Li-Anne H., et al. "Pembrolizumab Plus Lenvatinib as Second-line Treatment in Patients with Pleural Mesothelioma (PEMMELA): Cohort 2 of a Single-arm, Phase 2 Study." Lancet Oncology 26, no. 12 (2025): 1676. https://doi.org/10.1016/S1470-2045(25)00514-5.

MLA (9th ed.) Citation

Douma, Li-Anne H., et al. "Pembrolizumab Plus Lenvatinib as Second-line Treatment in Patients with Pleural Mesothelioma (PEMMELA): Cohort 2 of a Single-arm, Phase 2 Study." Lancet Oncology, vol. 26, no. 12, 2025, p. 1676, https://doi.org/10.1016/S1470-2045(25)00514-5.